Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT04290793
Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- AZ-VUB
- Target Recruit Count
- 63
- Registration Number
- NCT04224922
- Locations
- 🇧🇪
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
🇧🇪Imelda Ziekenhuis, Bonheiden, Belgium
🇧🇪Universitaire Ziekenhuis Antwerpen, Edegem, Belgium
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04214626
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1560
- Registration Number
- NCT04193059
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
- Conditions
- Breast CancerNeoadjuvant Chemotherapy
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 156
- Registration Number
- NCT04172259
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
- Conditions
- Breast CancerTriple-negative Breast CancerNab-paclitaxel
- Interventions
- Drug: Nab-paclitaxel + Carboplatin
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 520
- Registration Number
- NCT04138719
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT04137640
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Albumin-bound paclitaxel combined with carboplatin
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT04136782
- Locations
- 🇨🇳
The Second Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
- Conditions
- Primary Breast Cancer
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2079
- Registration Number
- NCT04127019
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04067037
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.